NASDAQ:GRCE

Grace Therapeutics Q3 2026 Earnings Results & Report

Grace Therapeutics logo
$1.71 -0.02 (-1.16%)
Closing price 04:00 PM Eastern
Extended Trading
$1.70 -0.01 (-0.35%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grace Therapeutics missed analyst earnings expectations in its Q3 2026 results, released February 12, 2026. The company reported EPS of -$0.14 versus the -$0.09 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
4:00 PM ET

Grace Therapeutics EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.09
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Grace Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grace Therapeutics Q3 2026 Earnings FAQ

Grace Therapeutics (NASDAQ:GRCE) reported earnings of -$0.14 per share for Q3 2026, missing the consensus estimate of -$0.09. The report was announced on Thursday, February 12, 2026.

Grace Therapeutics Earnings Headlines

Beyond NVDA: The World’s Next #1 Company?
This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.tc pixel
Grace: Fiscal Q2 earnings snapshot
See More Grace Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email.

About Grace Therapeutics

Grace Therapeutics (NASDAQ:GRCE) is a clinical-stage biopharmaceutical company developing medicines for rare and orphan diseases. Its drug candidates are designed to address conditions with limited treatment options, including neurological disorders.

The company’s pipeline includes GTX-104, a formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, as well as GTX-102 for ataxia-telangiectasia and GTX-101 for postherpetic neuralgia. These programs use alternative delivery approaches intended to address limitations associated with existing treatments.

Grace Therapeutics was formerly known as Acasti Pharma and adopted its current name as it focused on the development programs associated with Grace Therapeutics. The company’s candidates remain investigational and are not approved medicines.

View Grace Therapeutics Profile